India

Natco gets EUA for Baricitinib use for Covid-19 treatment | India News

HYDERPharma player Natco Pharma Limited on Monday said it has received emergency use authorisation approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from the Central Drugs Standard Control Organization (CDSCO).
Natco said it will be seeking a compulsory license for the drug, which is sold under the brand name Olumiant by Eli Lilly & Co, based on emergency use in light of the grave and serious public health emergency across India due to the Covid-19 pandemic.
The company said it is ready to launch the product this week to make it available to Covid-19 patients across India. The country is currently reeling from a shortage of various Covid-19 treatment regimens including Remdesivir
Baricitinib is a rheumatoid arthritis drug that is being used for the treatment of Covid-19 positive in combination with Remdesivir. Baricitinib acts as an inhibitor of janus kinase, which is a family of intracellular, non-receptor tyrosine kinases that send cytokine-mediated signals to the cell to make more cytokines.
Janus Kinase inhibitors like Baricitinib prevent this process by blocking the messaging pathway, thereby preventing a cytokine storm and calming down the immune system.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button